Clinical and pathological features of ovarian cancer in women with germ- line mutations of BRCA1

New England Journal of Medicine

Volumn 335, Issue 19, 1996, Pages 1413-1416

  Rubin, Stephen C ^a   Benjamin, Ivor ^a   Behbakht, Kian ^a   Takahashi, Hiroyuki ^a   Morgan, Mark A ^a   Livolsi, Virginia A ^a   Berchuck, Andrew ^b   Muto, Michael G ^c   Garber, Judy E ^d   Weber, Barbara L ^a   Lynch, Henry T ^e   Boyd, Jeff ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CHROMOSOME 17Q; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE ISOLATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; ADULT; AGE OF ONSET; AGED; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 10544220023     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199611073351901     Document Type: Article

References (20)

1. Lynch HT, Lynch JF, Conway TA. Hereditary ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill, 1993:189-217.
2. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families: the Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
3. Steichen-Gersdorf E, Gallion HH, Ford D, et al. Familial site-specific ovarian cancer is linked to BRCAI on 17q12-21. Am J Hum Genet 1994; 55:870-5.
4. Merajver SD, Frank TS, Xu J, et al. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res 1995;1:539-44.
5. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene RRCA1. Science 1994;266: 66-71.
6. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
7. Benjamin I, Noumoff JS, Carlson JA Jr, Giuntoli RL, Morgan M, Mikuta JJ. Database management for a gynecologic oncology service. Gynecol Oncol 1990;38:431-6.
8. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
10. Miller BA, Ries LAG, Hankey BF, et al., eds. SEER cancer statistics review, 1973-1990. Bethesda, Md.: National Cancer Institute, 1993. (NIH publication no. 93-2789.)
11. Ozols RF, Rubin SC, Dembo AJ, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practices of gynecologic oncology. Philadelphia: J.B. Lippincott, 1992:731-81.
12. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
13. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience. Cancer 1993;71:606-14.
14. Piver MS, Baker TR, Jishi MF, et al. Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer 1993;71:Suppl:582-8.
15. Buller RE, Andersen B, Connor JP, Robinson R. Familial ovarian cancer. Gynccol Oncol 1993;51:160-6.
16. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9.
17. Porter DE, Cohen BB, Wallace MR, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994;81:1512-5.
18. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
19. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, BRCA1 and BRCA2 gene linkage. Cancer 1996;77: 697-709.
20. Sankila R, Aaltonen L, Jarvinen HJ, Mecklin JP. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996;110:682-7.